Ardian's Neopharmed buys pharma company MDM

MDM CEO Antonio Maggi will stay on with the business and work with Neopharmed Gentili CEO Alessandro Del Bono in this new phase of expansion.

With this bolt-on, Neopharmed Gentili intends to consolidate its market position in Italy and expand its product offering.

Ardian bought a majority stake in Neopharmed Gentili in November 2018 from its parent company Mediolanum Farmaceutici, which is controlled by the Del Bono family. Following the deal, Mediolanum retained a minority stake in the business and Alessandro Del Bono was appointed as CEO and chair.

Ardian invested via LBO Fund VI, which held a €4bn final close in September 2016. In addition to the equity deployed by the fund, a debt package of an undisclosed amount was also provided to finance the deal.

Company
Founded in 1995 and based in Monza, MDM specialises in the production and distribution of drugs. The company employs 90 staff and generates EBITDA of €4m from revenues of €20m, Unquote understands.

People
Neopharmed Gentili – Alessandro Del Bono (CEO).
MDM – Antonio Maggi (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Portfolio management
• Southern Europe
• Healthcare
• Ardian (formerly Axa PE)
• Italy
• Build-up